A Phase 1 Multiple Ascending Dose Study of DS-3201b in Subjects With Lymphomas

Conditions

Non-Hodgkin's Lymphoma

Phase I

What is the purpose of this trial?

Brief Summary:

DS-3201b is an experimental drug. It is not approved for regular use. It can only be used in clinical research.

Adults with non-Hodgkin lymphoma (NHL) might be able to join this study if their disease:

  • has come back after remission
  • is not responding to current treatment

This study has two parts:

  1. Dose Escalation is to find the safe dose of DS-3201b that adults with advanced NHL can tolerate.
  2. Dose Expansion is to:
    • find out how effective DS-3201b is for rare types of NHL
    • collect additional safety data

  • Trial with
    Daiichi Sankyo
  • Start Date
    05/28/2019
  • End Date
    02/28/2019

I'm interested in volunteering

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 877.978.8348

Trial Image

For more information about this study, contact:

Laura Leary

  • Last Updated
    05/30/2019
  • Study HIC
    #2000024688